Sign In
NewsRadar

Press release centre

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.
   

Past Press Releases - Apogenix

June 3, 2015
Apogenix appoints Peter Willinger as new CFO
Apogenix, a next generation immuno-oncology company, announced today the appointment of Peter Willinger as Chief Financial Officer. More

November 16, 2009
Apogenix receives orphan drug designation for APG101 in the US
Apogenix receives orphan drug designation for APG101 in the US and positive opinion on orphan product designation in Europe. More

October 27, 2009
Apogenix significantly strengthens IP protection for its clinical lead compound APG101
Apogenix, a clinical stage biopharmaceutical company developing novel drugs for malignant and inflammatory diseases, today announced that the company ́s IP position on its lead candidate APG101 was significantly strengthened by two patents recently granted by the European Patent Office. More

July 29, 2009
Apogenix receives research grants of EUR 2.6 million as part of the Biotechnology Cluster Rhine-Neck
Apogenix, a biopharmaceutical company developing novel drugs for malignant and inflammatory diseases, today announced that the company has received federal research grants of EUR 2.6 million as one of the companies belonging to the Biotechnology Cluster Rhine-Neckar. More

May 12, 2009
Apogenix reports positive phase i results on its lead compound AGP101
Apogenix GmbH, a biopharmaceutical company developing novel drugs for malignant and inflammatory diseases, today reported clinical phase I results on its lead compound AGP101. More

October 7, 2008
Apogenix starts Phase I with its lead compound AGP101
Apogenix GmbH, a biopharmaceutical company developing novel drugs based on the targeted modulation of apoptosis (programmed cell death), today announced that the Company has started the clinical Phase I trial in healthy volunteers with its lead compound AGP101. More

September 19, 2008
Two grants to support Apogenix´ research / update financing round
Two grants totaling EUR 1.65 million by the German Federal Ministry of Education and Research (BMBF) to support Apogenix“ research More

April 30, 2008
Apogenix raises EUR 27.5m in Series B financing round
Apogenix GmbH, a biopharmaceutical company developing novel drugs based on the targeted modulation of apoptosis (programmed cell death), today announced the closing of its second financing round. More

Data


26,673
Tech investments
From our Online Data Service
17,217
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 25€24.0MInternet commerce
Feb 14€19.0MBiopharmaceuticals
Feb 14N/AInternet services
Feb 14€4.6MBusiness applications
Feb 13€13.0MBiopharmaceuticals
Feb 13€25.0MMedical devices
Feb 13€15.0MBusiness applications

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Jan 29
Yumpingo
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.